Published in Am J Med on August 01, 1994
Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev (1999) 12.90
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (1997) 3.06
In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother (1997) 3.01
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother (1997) 2.99
Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine (2011) 2.09
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol (2003) 1.82
Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature. Infection (2006) 1.40
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1996) 1.35
Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother (2001) 1.24
Emerging disease issues and fungal pathogens associated with HIV infection. Emerg Infect Dis (1996) 1.17
Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother (1998) 1.11
Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother (2000) 1.11
Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother (1998) 1.05
In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimicrob Agents Chemother (1999) 1.03
Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis (2006) 0.99
Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections. Antimicrob Agents Chemother (2000) 0.98
Reflections on the approach to treatment of a mycologic disaster. Antimicrob Agents Chemother (2013) 0.96
Semi-invasive aspergillosis in an immunocompetent patient with Swyer-James-MacLeod Syndrome: a case report. J Med Case Rep (2010) 0.96
Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis (2005) 0.92
Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother (1996) 0.90
How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care (2014) 0.89
A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother (2013) 0.89
Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer (2003) 0.84
Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis (2010) 0.82
Incidence of invasive aspergillosis following remission-induction chemotherapy for acute leukemia: a retrospective cohort study in a single Canadian tertiary care centre. CMAJ Open (2014) 0.81
An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. Can J Infect Dis Med Microbiol (2004) 0.80
Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis (1997) 0.79
Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration. Antimicrob Agents Chemother (2012) 0.78
History of medical mycology in the united states. Clin Microbiol Rev (1996) 0.78
Low-dose cyclophosphamide-induced acute hepatotoxicity. Am J Case Rep (2013) 0.76
In vitro and in vivo activities of syn2836, syn2869, syn2903, and syn2921: new series of triazole antifungal agents. Antimicrob Agents Chemother (2001) 0.76
Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis (2003) 0.76
Practical modalities for prevention of fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis (1997) 0.76
Treatment options in Invasive Aspergillosis. Curr Treat Options Infect Dis (2014) 0.75
Comparison of efficacy of amphotericin B and itraconazole in chronic invasive fungal sinusitis. Indian J Otolaryngol Head Neck Surg (2012) 0.75
Excellent outcome of Aspergillous endophthalmitis in a case of allergic bronchopulmonary aspergillosis. Indian J Ophthalmol (2014) 0.75
Antifungal clinical trials and guidelines: what we know and do not know. Cold Spring Harb Perspect Med (2014) 0.75
Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria. Eur J Clin Microbiol Infect Dis (2013) 0.75
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med (1999) 9.84
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother (1993) 8.36
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med (1987) 5.74
Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity (1999) 5.34
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1986) 4.97
Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother (1995) 4.92
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother (1989) 4.00
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis (1991) 3.88
Treatment of invasive aspergillosis with itraconazole. Am J Med (1989) 3.87
Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. Antimicrob Agents Chemother (1984) 3.74
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 3.53
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med (1994) 3.32
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int (2007) 3.17
Methicillin-resistant Staphylococcus aureus: colonization and infection in a long-term care facility. Ann Intern Med (1991) 3.03
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 3.02
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Cell-mediated immunity in Cryptococcosis. Cell Immunol (1974) 2.68
Inactivation of the Porphyromonas gingivalis fimA gene blocks periodontal damage in gnotobiotic rats. J Bacteriol (1994) 2.59
Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol (1995) 2.54
The role of understaffing in central venous catheter-associated bloodstream infections. Infect Control Hosp Epidemiol (1996) 2.44
Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med (1994) 2.44
A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome. N Engl J Med (1990) 2.39
Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrob Agents Chemother (1990) 2.37
Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 2.36
The Drosophila RAD21 cohesin persists at the centromere region in mitosis. Curr Biol (2000) 2.29
Coccidioidomycosis. Part I. Am Rev Respir Dis (1978) 2.25
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis (2001) 2.25
Male circumcision: a South Korean perspective. BJU Int (1999) 2.24
Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. Am J Med (1989) 2.20
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol (1996) 2.19
The clinical outcome of abdominoplasty performed under conscious sedation: increased use of fentanyl correlated with longer stay in outpatient unit. Plast Reconstr Surg (1999) 2.18
Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. Aliment Pharmacol Ther (2013) 2.17
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol (1998) 2.16
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis (1995) 2.11
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis (2007) 2.09
Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis (1996) 2.09
Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis (2000) 2.08
CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol (2001) 2.07
Rubella virus replication complexes are virus-modified lysosomes. Virology (1998) 2.07
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Remodelling of nasal mucosa in mild and severe persistent allergic rhinitis with special reference to the distribution of collagen, proteoglycans, and lymphatic vessels. Clin Exp Allergy (2010) 2.04
In vitro susceptibility of Nocardia asteroides to 25 antimicrobial agents. Antimicrob Agents Chemother (1984) 2.03
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother (2001) 2.03
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis (1984) 2.03
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med (1992) 2.01
Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur J Biochem (1991) 1.95
Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies. Am J Med (1976) 1.93
Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res (1980) 1.92
Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis (2011) 1.92
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med (1996) 1.91
Nosocomial pneumonia. A continuing major problem. Am Rev Respir Dis (1973) 1.91
Staphylococcus aureus nasal colonization in a nursing home: eradication with mupirocin. Infect Control Hosp Epidemiol (1990) 1.90
Cell-free immunity in Cecropia. A model system for antibacterial proteins. Eur J Biochem (1991) 1.90
Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol (1998) 1.88
Molecular cloning, cDNA sequencing, and chemical synthesis of cecropin B from Hyalophora cecropia. Proc Natl Acad Sci U S A (1985) 1.85
Single-concentration broth microdilution test for detection of high-level aminoglycoside resistance in enterococci. J Clin Microbiol (1987) 1.85
Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med (1993) 1.83
Role for ceramide in cell cycle arrest. J Biol Chem (1995) 1.83
Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Antimicrob Agents Chemother (1996) 1.83
Coccidioidomycosis. Part II. Am Rev Respir Dis (1978) 1.83
Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. Endoscopy (2012) 1.81
Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 1.80
Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. The AHA Technical Panel on Infections Within Hospitals. Infect Control Hosp Epidemiol (1994) 1.79
6,7-Bis(bromomethyl)-2,11,18,21,24-pentaoxatetracyclo. Acta Crystallogr C (2001) 1.79
Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis (1982) 1.77
Isolation and in vivo and in vitro antifungal activity of phenylacetic acid and sodium phenylacetate from Streptomyces humidus. Appl Environ Microbiol (2001) 1.77
Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother (1981) 1.77
Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis (1993) 1.76
Cloning and sequencing of a Candida albicans catalase gene and effects of disruption of this gene. Infect Immun (1998) 1.76
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74
Role of ceramide in cellular senescence. J Biol Chem (1995) 1.74